Financials

sarepta building
Favicon Fierce Pharma

Sarepta CEO to retire, citing 'shocking and ironic twist of fate'

Ingram’s departure comes at a crossroads for Sarepta, as the unwavering conviction that defined his tenure faces major commercial uncertainty.
Angus Liu Feb 26, 2026 11:30am
Astellas
Favicon Fierce Pharma

Astellas lifts forecast as Vyloy surge counters trial miss

Feb 5, 2026 11:00am
Illustration connected puzzle pieces with the acronym MA
Favicon Fierce Pharma

Halozyme catches M&A wave to snap up Surf Bio

Jan 28, 2026 2:06pm
Naoki Okamura
Favicon Fierce Pharma

Astellas CEO resists 'rescue BD' as Xtandi patent cliff nears

Jan 15, 2026 10:42am
Legend
Favicon Fierce Pharma

J&J, Legend pull ASH paper comparing Carvykti to rival CAR-T

Nov 12, 2025 11:36am
sarepta building
Favicon Fierce Pharma

Sarepta, despite key trial flop, will seek full nod for DMD meds

Nov 4, 2025 7:56am